Display options
Cite
Flamm SL, Pockros PJ, Bengtsson L, et al. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014;2(2):65-73doi: 10.14218/JCTH.2014.00007.
Flamm, S. L., Pockros, P. J., Bengtsson, L., & Friedman, M. (2014). Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. Journal of clinical and translational hepatology, 2(2), 65-73. https://doi.org/10.14218/JCTH.2014.00007
Flamm, Steven L, et al. "Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study." Journal of clinical and translational hepatology vol. 2,2 (2014): 65-73. doi: https://doi.org/10.14218/JCTH.2014.00007
Flamm SL, Pockros PJ, Bengtsson L, Friedman M. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15. PMID: 26356545; PMCID: PMC4521261.
Copy Download .nbib Format: NLM
Share it on

J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15.

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.

Journal of clinical and translational hepatology

Steven L Flamm, Paul J Pockros, Leif Bengtsson, Mark Friedman

Affiliations

  1. Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
  2. Scripps Clinic and Scripps Translational Science Institute, La Jolla, California, USA.
  3. Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.

PMID: 26356545 PMCID: PMC4521261 DOI: 10.14218/JCTH.2014.00007

Abstract

BACKGROUND AND AIMS: There is a paucity of information regarding similarities and differences between patients from the phase 3 studies of telaprevir and those receiving telaprevir in clinical practice.

METHODS: This retrospective chart review evaluated baseline characteristics and follow-up safety and tolerability data for patients with hepatitis C virus (HCV) infection treated with telaprevir and peginterferon alfa and ribavirin (PR) in clinical practice.

RESULTS: In total, 338 charts from patients at four academic and three community US treatment centers who received telaprevir and PR and had at least 12 weeks of follow-up data were included; 62% were from academic centers and 38% were from community centers. Of the 338 patients, 269 completed 12 weeks of telaprevir and PR; 32 discontinued due to adverse events. Mean age was 55 years; patients were predominantly white (79.3%) males (58.9%) with genotype 1a HCV infection (61.8%); 35.5% were reported to have cirrhosis at baseline; and 55.3% previously received PR. Hypertension and depression were the most common comorbidities. Patient characteristics outside the per-protocol minimum criteria used in the phase 3 studies of telaprevir were, e.g., hemoglobin, 9.2%; albumin, 5.3%; platelets, 11.5%; and neutrophil count, 5.6%. Adverse events occurred in 329/338 (97.3%) patients, with anemia, fatigue, nausea, and rash being the most common. Of 38 hospitalizations, 26 were deemed related to telaprevir and PR. Three patients died due to pneumonia, septic shock, and hepatorenal syndrome (n=1 each).

CONCLUSIONS: These findings complement those reported from rigorous, randomized controlled studies with telaprevir-based treatment and provide a general assessment of similarities and/or differences between patients from the phase 3 studies of telaprevir and those treated with telaprevir in clinical practice.

Keywords: Combination drug therapy; Hepatitis C virus; Liver diseases; Protease inhibitors

References

  1. BMC Infect Dis. 2013 May 23;13:234 - PubMed
  2. J Clin Gastroenterol. 2009 Aug;43(7):686-91 - PubMed
  3. Ann Intern Med. 2011 Sep 20;155(6):353-60 - PubMed
  4. Qual Manag Health Care. 2005 Oct-Dec;14(4):206-16 - PubMed
  5. J Hepatol. 2013 Sep;59(3):434-41 - PubMed
  6. Aliment Pharmacol Ther. 2013 Jul;38(2):124-33 - PubMed
  7. N Engl J Med. 2011 Sep 15;365(11):1014-24 - PubMed
  8. J Can Acad Child Adolesc Psychiatry. 2006 Aug;15(3):126-34 - PubMed
  9. N Engl J Med. 2011 Jun 23;364(25):2417-28 - PubMed
  10. N Engl J Med. 2011 Jun 23;364(25):2405-16 - PubMed
  11. Dig Dis Sci. 2011 Oct;56(10 ):3024-31 - PubMed
  12. Respir Care. 2004 Oct;49(10):1171-4 - PubMed
  13. Value Health. 2007 Sep-Oct;10(5):326-35 - PubMed
  14. Value Health. 1999 Mar-Apr;2(2):73-7 - PubMed
  15. J Clin Pharmacol. 2007 Sep;47(9):1074-86 - PubMed

Publication Types